Zufferey J, Hohlfeld P, Bille J, Fawer C L, Blanc D, Pinon J M, Vaudaux B
Department of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Pediatr Infect Dis J. 1999 Nov;18(11):971-5. doi: 10.1097/00006454-199911000-00007.
The transplacental transfer of specific maternal IgG antibodies makes the diagnosis of congenital Toxoplasma infection quite difficult in the neonate. The enzyme-linked immunofiltration assay (ELIFA), comparing at delivery the immunologic profile of the mother's antibody response and that of her child, allows discrimination between IgG antibodies of maternal origin and IgGs synthesized by the fetus.
To evaluate the diagnostic reliability of the comparative ELIFA for diagnosing congenital Toxoplasma infection as well as the reliability of testing for IgM- and IgA-specific antibodies in cord blood.
From November, 1991, to December, 1995, an ELIFA was prospectively performed at delivery on blood samples obtained from 227 women with primary Toxoplasma infection during pregnancy and from their infants. For each child the ELIFA result was evaluated in relation to the serologic follow-up: disappearance of specific anti-Toxoplasma gondii IgG antibodies in the absence of treatment before 12 months of age indicating an uninfected child, as opposed to persistence beyond 12 months of age indicative of a congenital infection.
Of 227 children 139 were lost to follow-up. Among the 88 children available for follow up, the ELIFA was negative in 70 infants, 69 of whom were confirmed to be uninfected. Thirteen of these 69 cord blood ELIFA-negative samples were positive for anti-T. gondii IgM and/or IgA detected by means of a conventional immunosorbent agglutination assay. Of the remaining 18 children (representing 75% of all new cases of congenital toxoplasmosis diagnosed during the study period at our institution), the ELIFA was positive in 16, negative in 1 and inconclusive in 1.
The ELIFA test is a valuable tool for diagnosing congenital T. gondii infection and in differentiating between true neonatal infection and cord blood contamination. In our experience the diagnostic sensitivity of the ELIFA test was 94.1% and the specificity was 98.6%. The cord blood was contaminated by specific maternal anti-T. gondii IgA and/or IgM in as many as 20% of the cases.
特定母体IgG抗体的胎盘转运使得新生儿先天性弓形虫感染的诊断相当困难。酶联免疫过滤试验(ELIFA)通过在分娩时比较母亲抗体反应和其孩子的免疫特征,能够区分母体来源的IgG抗体和胎儿合成的IgG抗体。
评估比较性ELIFA诊断先天性弓形虫感染的诊断可靠性以及脐血中IgM和IgA特异性抗体检测的可靠性。
从1991年11月至1995年12月,前瞻性地对227名孕期原发性弓形虫感染妇女及其婴儿分娩时采集的血样进行ELIFA检测。对于每个孩子,根据血清学随访评估ELIFA结果:12个月龄前未经治疗时特异性抗弓形虫IgG抗体消失表明孩子未感染;相反,如果抗体持续超过12个月龄则表明先天性感染。
227名儿童中有139名失访。在可进行随访的88名儿童中,70名婴儿的ELIFA检测为阴性,其中69名被证实未感染。这69份脐血ELIFA阴性样本中有13份通过传统免疫吸附凝集试验检测抗弓形虫IgM和/或IgA呈阳性。其余18名儿童(占我们机构在研究期间诊断的所有先天性弓形虫病新病例的75%)中,16名ELIFA检测为阳性,1名阴性,1名结果不确定。
ELIFA检测是诊断先天性弓形虫感染以及区分真正的新生儿感染和脐血污染的有价值工具。根据我们的经验,ELIFA检测的诊断敏感性为94.1%,特异性为98.6%。多达20%的病例中脐血被母体特异性抗弓形虫IgA和/或IgM污染。